With heightened government scrutiny on educational forums, biopharma manufacturers need a sound framework that demonstrates they are following best practices.
Travel is ramping back up, and live events are possible again. Many life sciences companies are restarting speaker programs, which were put on hold at the start of the pandemic more than two years ago. But companies can’t simply go back to the policies and practices that used to determine their involvement and investment.